The rising frequency of cluster headache patients with a positive family history, the development of innovative therapies for the treatment of CH, and the growing worldwide elderly population are likely to propel the global cluster headache market forward. The FDA's rising approval of innovative medicines for the treatment of cluster headache is expected to present a valuable opportunity for pharmaceutical companies. The global market for cluster headaches is being held back by a lack of provider awareness and unfavourable healthcare policies that have a detrimental effect on total healthcare costs. The coronavirus pandemic has had a detrimental effect on pharmaceutical product research, production, and supply, as well as the expansion of the drugs used to treat CH illness produced by several corporations around areas including North America, Europe, and Asia Pacific. Furthermore, the worldwide lockdown imposed during the COVID-19 epidemic has hampered pharmaceutical product manufacture and supply. Furthermore, due to public health measures implemented by the government to contain the pandemic, people's screen time during COVID-19 has continued to rise, driving the worldwide market for cluster headache.
According to Coherent Market Insights, the global Cluster Headache Market is estimated to be valued at US$ 355.2 Million in 2021 and is expected to increase to US$ 550.1 Million by 2028, witnessing a CAGR of 6.4% over the forecast period (2021-2028).
Key Companies in the Cluster Headache Industry:
1. F. Hoffmann-La Roche
Roche Holding AG engages in the pharmaceuticals and diagnostics. The company was founded in 1896 and is headquartered in Basel, Switzerland.
2. Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. Taked, Zedira and Dr. Falk Pharma GmbH in October, 2022 announced a collaboration and licensing agreement to develop ZED1227/TAK-227, a Phase 2b investigational therapy for the treatment of celiac disease. Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors on January 10, 2022.
3. AstraZeneca GmbH
AstraZeneca PLC was incorporated in 1992.The company is headquartered in Cambridge, the United Kingdom and operational in more than 100 countries. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. On June 07, 2017 - The Grünenthal Group announced that it has entered into an agreement with AstraZeneca for the global rights to Zomig® (Zolmitriptan) excluding Japan. Zomig® is indicated for the acute treatment of migraines and cluster headaches.
4. Sanofi S.A.
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions and was founded in 1973. The company is headquartered in Paris, France and is operational in 100 plus countries. Sanofi and Innate Pharma SA announced in December, 2022 an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform.
5. Allergan
Allergan, is a multi-specialty healthcare company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential to see more clearly, move more freely, express themselves more fully. In 1950. Allergan focused on the discovery and development of novel formulations for specialty markets, as well as intimate collaboration with physicians and the scientific community. The company is headquartered in Dublin, Ireland.
6. Novartis AG.
The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. On March 2022, Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy.
7. Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company was founded in 1983 and is based in Mumbai, India.
8. Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
9. AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide since 2012. It is headquartered in North Chicago and operational in more than 70 countries. AbbVie and HotSpot Therapeutics, Inc., in December, 2022 announced an exclusive worldwide collaboration and option to license agreement for HotSpot's discovery-stage IRF5 program for the treatment of autoimmune diseases.
*Definition - Cluster headache (CH) is a relatively uncommon kind of headache. The episode lasts 15 minutes to three hours and happens on a daily or nearly daily basis for weeks or months. The reasons of cluster headache appear to be connected to the body's abrupt release of histamine or serotonin in the region of the trigeminal nerve, which is located in the face.
